PI3K-mTOR in Cancer and Cancer Therapy
Springer International Publishing (Verlag)
978-3-319-81704-0 (ISBN)
Nandini Dey, M.S., Ph.D., is a Senior Scientist Head of Cancer Biology, Avera Cancer Institute Center for Precision Oncology. She is also Assistant Professor of the Department of Internal Medicine at The University of South Dakota Sanford School of Medicine. Dey has more than 20 years of experience in translational research and has authored or co-authored more than 80 publications.< Pradip De, M.S., Ph.D., is a Senior Scientist Head of Translational Oncology, Avera Cancer Institute Center for Precision Oncology. He is also Assistant Professor of the Department of Internal Medicine at The University of South Dakota Sanford School of Medicine. De has more than 20 years of experience in translational research in academics and industry and has authored or co-authored more than 90 publications. Brian Leyland-Jones, MB BS, Ph.D. is Vice President of Avera Cancer Institute Center for Precision Oncology. Dr. Leyland-Jones is a consulting professor at the Stanford University School of Medicine. He is an internationally renowned breast cancer expert with more than 35 years experience in patient care and research, has published over 170 papers and has received over 11,000 citations in his scientific career.
PI3K-Akt-mTOR Signaling in Cancer and Cancer Therapeutics.- Part 1: PI3K-mTOR Pathway in Cancers.- The mTOR Complexes in Cancer Cell Metabolism.- PI3K-AKT-mTOR Pathway Co-operates with the DNA Damage Repair Pathway: Carcinogenesis in Triple Negative Breast Cancers and Beyond.- The AKT-mTOR Signaling Pathway for Drug Response Prediction and Prognostic Signatures.- Resistance to PI3K Pathway Inhibition.- Part 2: PI3K-mTOR Pathway in Cancer Medicine.- Combination Therapies Targeting the PI3K/AKT/mTOR Pathways.- Phospho-Inositol-3-Kinase Activity and Dysregulation in Pediatric Leukemia and Lymphoma.- HER2 Signaling Network in Advanced Breast Cancer: Opportunities for Combination Therapies.- The PI3K-mTOR Pathway in Prostate Cancer: Biological Significance and Therapeutic Opportunities.
Erscheinungsdatum | 05.03.2022 |
---|---|
Reihe/Serie | Cancer Drug Discovery and Development |
Zusatzinfo | XXIV, 294 p. 31 illus. in color. |
Verlagsort | Cham |
Sprache | englisch |
Maße | 155 x 235 mm |
Gewicht | 4861 g |
Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Mikrobiologie / Infektologie / Reisemedizin |
Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie | |
Medizin / Pharmazie ► Studium | |
Schlagworte | antibacterial drug resistance • Apoptosis • Cancer • Cancer Metabolism • drug development • drug resistance • signaling pathway |
ISBN-10 | 3-319-81704-3 / 3319817043 |
ISBN-13 | 978-3-319-81704-0 / 9783319817040 |
Zustand | Neuware |
Haben Sie eine Frage zum Produkt? |
aus dem Bereich